A COMPREHENSIVE EVALUATION OF THE RS713041 (C718T) GPX4 GENE POLYMORPHISM AND BIOCHEMICAL PARAMETERS IN THE PATHOGENESIS OF CARDIOTOXIC COMPLICATIONS IN ACUTE LEUKEMIA
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Main Article Content
Abstract:
The development of cardiotoxicity is characterized by significant interindividual variability. Even with similar chemotherapy regimens, the severity of myocardial damage varies significantly, indicating the involvement of individual, including genetically determined, myocardial vulnerability factors. Oxidative stress, which leads to cardiomyocyte damage, impaired contractile function, and the development of electrical instability, is considered one of the key mechanisms of cardiotoxic damage. In recent years, particular attention has been paid to ferroptosis, an iron-dependent form of regulated cell death caused by the accumulation of lipid peroxidation products.
Article Details
How to Cite:
References:
Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014; 64(9):938–945.
Carvalho C. et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009; 16(25):3267–3285.
Zhang S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639–1642.
Renu K. et al. Molecular mechanism of doxorubicin-induced cardiomyopathy – An update. Eur J Pharmacol. 2018; 818:241–253.
Nduom E.K. et al. Oxidative stress in cancer and cardiovascular disease: a review of pathogenesis and treatment. Oxid Med Cell Longev. 2013; 2013:1–8.
Niforou K. et al. The Role of Oxidative Stress in Cardiovascular Disease. J Mol Sci. 2015; 16(8):18191–18201.
Andreassi M.G. et al. Genetic variants and oxidative stress: a dangerous liaison for cardiovascular disease and cancer. Mutat Res. 2009; 667(1–2):35–42.
George J. et al. The role of BNP and NT-proBNP in the diagnosis and management of heart failure. Heart. 2008; 94(7):886–892.
McDonagh T.A. et al. NT-proBNP and its clinical utility in cardiovascular disease. Eur Heart J. 2021; 42(36):3716–3729.
Murtagh G. et al. Cardiac biomarkers in the management of adult cancer patients. J Clin Oncol. 2017; 35(35):4050–4058.